The present invention relates to a method for preparing a three-dimensionally cultured skin model comprising dermis and epidermis, which comprises: a step of preparing the dermis using a composition comprising murine fibroblasts; and native collagen or a combination of native collagen and atelocollagen; and a step of forming the epidermis using keratinocytes. Also, the present invention relates to a three-dimensionally cultured skin model which comprises: a dermis prepared by a composition comprising murine fibroblasts, native collagen, or a combination of native collagen and atelocollagen; and epidermis formed from keratinocytes. The three-dimensionally cultured skin model of the present invention may be used widely in toxicity and efficacy experiments of medicines or cosmetics, and in the field of alternative experiments for animal experiments since the three-dimensionally cultured skin model is excellent in formation and differentiation of dermis and epidermis using murine 3T3 cells for preparing the skin model and a mixture of atelocollagen and native collagen, and has a structure similar to the human skin layer by inhibiting dermal contraction and collagen degradation in the dermis.

Cell-free compositions for promoting restoration of tissue function or enhancement of tissue function and methods of stimulating or promoting restoration or enhancement of tissue function using the cell-free compositions. The compositions herein help stimulate endogenous pathways via a subject's own cells effectively for improving tissue function, enhancing tissue function, enhancing cell proliferation, etc. The compositions comprise one or a plurality of therapeutic components such as growth factors, extracellular matrix, DNA, RNA, hormones, drugs, cell surface receptors, enzymes, cytokines, angiogenesis modulating factors, etc., e.g., any material that can effectively activation endogenous pathways in the subject's own cell to a desired effect. The cell-free composition comprises a carrier or is attached to or integrated into and/or within a carrier. The carrier may help provide for containment of the therapeutic components and/or provide for time-release of the therapeutic components of the cell-free composition.

The present disclosure provides ex vivo chamber-specific cardiac tissues, methods for generating the cardiac tissues in a bioreactor, and methods of using the cardiac tissues. Examples of cardiac tissues that can be generated include, but are not limited to, atrial tissues, ventricular tissues, and composite tissues having an atrial tissue connected to a ventricular tissue.

A method for manufacturing a skin chip according to an exemplary embodiment of the present disclosure may include: a step of forming first and second PDMS layers disposed on both surfaces of a porous membrane and each having a microfluidic channel through which a culture medium is transferred to both surfaces of the porous membrane; a step of forming first and second MEA substrate layers disposed on the outer surfaces of the first and second PDMS layers, respectively, and having metal electrodes for measurement of TEER arranged at positions corresponding to the channels; and a step of forming first and second PMMA layers disposed on the outer surfaces of the first and second MEA substrate layers, respectively. In the method for manufacturing a skin chip according to in an exemplary embodiment of the present disclosure, the porous membrane may be made of a polycarbonate having pores of a predetermined size.

This disclosure is in the field of cancer immunotherapy and relates to all cancer types, including but not limited to cancers of the breast, lung, prostate, pancreas, colon, bladder, brain, head-neck, kidney, esophagus, skin, and blood cells. The embodiments provide methods for selecting and amplifying specific targeting molecules to use in therapy and diagnostic testing. Targets include but are not necessarily limited to architecturally preserved, usually heterogeneous specific surface structures present on individual cancer cells and cancer stem cells but not on non-malignant cells. The embodiments are novel in that they provide these binding molecules for one individual's cancer regardless of the rarity of an individual cancer cell or stem cell and promptly enough to initiate treatment without requiring lengthy immunization or hybridoma production that are current art.

Provided herein are methods and systems for bio-printing of three-dimensional organs and organoids. Also provided herein are bio-printed three-dimensional organs and organoids for use in the generation and/or the assessment of immunological products and/or immune responses. Also provided herein are methods and system for bio-printing three-dimensional matrices.

A method for obtaining a composition for tissue regeneration, providing M2-macrophages, co-culturing the M2-macrophages with tissue-specific cells in serum free medium; and collecting the supernatant of the co-culture. The compositions obtained by this method are suitable in medicine regenerative treatments, able to regenerate injured tissue. These products are sterile cell-free physiological aqueous solutions that show specific tissue concentration patterns to provide optimal tissue-specific regenerative effects. The compositions may be stored for long periods cryopreserved or lyophilized until its use, avoiding any subsequent blood extraction from the cell-donor, the stored growth factors and/or cytokines biologically active after long-term storage. Moreover, the compositions may be potentially applied in both autologous and allogenic treatments.

The present invention provides methods for cellular seeding onto three-dimensional fibroblast constructs, three-dimensional fibroblast constructs seeded with muscle cells, and uses therefore.

The present invention is drawn, in part, to biocompatible compositions comprising a biocompatible polymer matrix and conditioned cell medium comprising i) a cell culture medium and ii) one or more agents synthesized by and secreted from one or more cells cultured in the cell culture medium, as well as therapeutic uses thereof, particularly in modulating bone and/or gum tissue growth.

A method for producing a cell population containing liver progenitor cells, including the steps of

(1) preparing a culture substratum containing a cell population comprising liver progenitor cells and fibroblasts,
(2) physically removing the fibroblast colony from the culture substratum,
(3) detaching cells from the culture substratum, and recovering the detached cells, and
(4) culturing the cells recovered in the step (3) on a collagen-coated culture substratum, and recovering the cells not adhered to the culture substratum is provided by the present invention.